Plasma Matrix Metalloproteinase-9 Level Is Correlated With Left Ventricular Volumes and Ejection Fraction in Patients With Heart Failure

Journal of Cardiac Failure

Volumn 12, Issue 7, 2006, Pages 514-519

  Yan, Andrew T ^a   Yan, Raymond T ^a   Spinale, Francis G ^d   Afzal, Rizwan ^b   Gunasinghe, Himali R ^d   Arnold, Malcolm ^c   Demers, Catherine ^b   Mckelvie, Robert S ^b   Liu, Peter P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Ejection fraction; Heart failure; Matrix metalloproteinase; Remodeling

Indexed keywords

CANDESARTAN; ENALAPRIL; GELATINASE A; GELATINASE B; METOPROLOL; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SCINTIANGIOGRAPHY; TIME SERIES ANALYSIS;

EID: 33748283150     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2006.05.012     Document Type: Article

References (33)

1. Spinale F.G. Matrix metalloproteinases. Regulation and dysregulation in the failing heart. Circ Res 90 (2002) 520-530
2. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?. Circulation 108 (2003) 1395-1403
3. Mann D.L., and Spinale F.G. Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. Circulation 98 (1998) 1699-1702
4. Coker M.L., Thomas C.V., Clair M.J., Hendrick J.W., Krombach R.S., Galis Z.S., et al. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol 274 (1998) H1516-H1523
5. Spinale F.G., Coker M.L., Thomas C.V., Walker J.D., Mukherjee R., and Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 82 (1998) 482-495
6. Sun M., Dawood F., Wen W.H., Chin M.Y., Kirshenbaum L., and Liu P.P. Excessive tumor necrosis factor activation post-infarction contributes to susceptibility to myocardial rupture and left ventricular dysfunction. Circulation 110 (2004) 3221-3228
7. Nishikawa N., Yamamoto K., Sakata Y., Mano T., Yoshida J., Miwa T., et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res 57 (2003) 766-774
8. Wilson E.M., Moainie S.L., Baskin J.M., Lowry A.S., Deschamps A.M., Mukherjee R., et al. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation 107 (2003) 2857-2863
9. Rohde L.E., Ducharme A., Arroyo L.H., Aikawa M., Sukhova G.H., Lopez-Anaya A., et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99 (1999) 3063-3070
10. Spinale F.G., Coker M.L., Krombach S.R., Mukherjee R., Hallak H., Houck W.V., et al. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 85 (1999) 364-376
11. Peterson J.T., Hallak H., Johnson L., Li H., O'Brien P.M., Sliskovic D.R., et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 103 (2001) 2303-2309
12. Mukherjee R., Brinsa T.A., Dowdy K.B., Scott A.A., Baskin J.M., Deschamps A.M., et al. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 107 (2003) 618-625
13. Ducharme A., Frantz S., Aikawa M., Rabkin E., Lindsey M., Rohde L.E., et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106 (2000) 55-62
14. Tyagi S.C., Campbell S.E., Reddy H.K., Tjahja E., and Voelker D.J. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem 155 (1996) 13-21
15. Thomas C.V., Coker M.L., Zellner J.L., Handy J.R., Crumbley A.J., and Spinale F.G. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97 (1998) 1708-1715
16. Li Y.Y., Feldman A.M., Sun Y., and McTiernan C.F. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98 (1998) 1728-1734
17. Spinale F.G., Coker M.L., Heung L.J., Bond B.R., Gunasinghe H.R., Etoh T., et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102 (2000) 1944-1949
18. Reinhardt D., Sigusch H.H., Hensse J., Tyagi S.C., Korfer R., and Figulla H.R. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 88 (2002) 525-530
19. Wilson E.M., Gunasinghe H.R., Coker M.L., Sprunger P., Lee-Jackson D., Bozkurt B., et al. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 8 (2002) 390-398
20. Ohtsuka T., Hamada M., Saeki H., Ogimoto A., Hara Y., Shigematsu Y., et al. Serum levels of matrix metalloproteinases and tumor necrosis factor-alpha in patients with idiopathic dilated cardiomyopathy and effect of carvedilol on these levels. Am J Cardiol 91 (2003) 1024-1027
21. Altieri P., Brunelli C., Garibaldi S., Nicolino A., Ubaldi S., Spallarossa P., et al. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 33 (2003) 648-656
22. Tsuyuki R.T., Yusuf S., Rouleau J.L., Maggioni A.P., McKelvie R.S., Wiecek E.M., et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: Design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol 13 (1997) 1166-1174
23. McKelvie R.S., Yusuf S., Pericak D., Avezum A., Burns R.J., Probstfield J., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure-Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Circulation 100 (1999) 1056-1064
24. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy-The Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study. Circulation 101 (2000) 378-384
25. Li Y.Y., Feng Y., McTiernan C.F., Pei W., Moravec C.S., Wang P., et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 104 (2001) 1147-1152
26. Schwartzkopff B., Fassbach M., Pelzer B., Brehm M., and Strauer B.E. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 4 (2002) 439-444
27. Rouet-Benzineb P., Buhler J.M., Dreyfus P., Delcourt A., Dorent R., Perennec J., et al. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail 1 (1999) 337-352
28. Squire I.B., Evans J., Ng L.L., Loftus I.M., and Thompson M.M. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 10 (2004) 328-333
29. Kai H., Ikeda H., Yasukawa H., Kai M., Seki Y., Kuwahara F., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32 (1998) 368-372
30. Sakata Y., Yamamoto K., Mano T., Nishikawa N., Yoshida J., Hori M., et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 109 (2004) 2143-2149
31. Mizon-Gerard F., de Groote P., Lamblin N., Hermant X., Dallongeville J., Amouyel P., et al. Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. Eur Heart J 25 (2004) 688-693
32. Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107 (2003) 1579-1585
33. Sundstrom J., Evans J.C., Benjamin E.J., Levy D., Larson M.G., Sawyer D.B., et al. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur Heart J 25 (2004) 1509-1516